- Home
- ARQT vs GBDC Comparison
ARQT vs GBDC Comparison
Compare ARQT & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARQT | GBDC |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ARQT | GBDC |
|---|---|---|
| Price | $24.58 | $12.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $31.86 | $14.17 |
| AVG Volume (30 Days) | 1.2M | ★ 2.8M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.87% |
| EPS Growth | ★ 88.79 | 4.41 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $376,072,000.00 | N/A |
| Revenue This Year | $34.46 | N/A |
| Revenue Next Year | $29.77 | N/A |
| P/E Ratio | ★ N/A | $48.62 |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $11.86 | $11.77 |
| 52 Week High | $31.77 | $15.63 |
Technical Indicators
Market Signals| Indicator | ARQT | GBDC |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 41.06 |
| Support Level | $22.26 | $11.77 |
| Resistance Level | $27.65 | $14.03 |
| Average True Range (ATR) | 1.54 | 0.28 |
| MACD | -0.18 | 0.04 |
| Stochastic Oscillator | 29.08 | 45.00 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.